Abstract 4976
Background
Recent studies have identified a complex but definitive role of germline DNA in cancer predisposition. Archived formalin-fixed paraffin-embedded (FFPE) samples from cancer patients are vital for several molecular and genomic studies. For retrospective studies investigating gene mutations, loss of heterozygosity and copy number changes, non-tumoral FFPE samples can be used as a source of germline DNA. The key challenge with FFPE DNA purification is usually due to the fixation process, which causes cross-linking and fragmentation of FFPE DNA. In spite of the development of several techniques for FFPE DNA extraction, automated extraction can provide efficient DNA purification with the least hands-on and the least contamination. We compared two different automated approaches with special focus on DNA yield and quality using the DNA integrity number (DIN) value.
Methods
The study was carried out on 48 non-tumoral FFPE samples from cancer patients. Two FFPE pretreatment methods were used simultaneously: GeneRead DNA FFPE Kit (removes cytosine deamination artifacts from FFPE) and QIAsymphony DSP DNA Kit. After the initial pretreatment, the extraction step was performed using the automated QIAsymphony SP instrument for both methods. Finally, the purified DNA was assessed using TapeStation for measuring the concentration and DIN value.
Results
The median DNA concentration using the GeneRead method was 13.85 ng/ul (1.13-111 ng/ul), while for QIAsymphony DSP the median DNA was 5.3 ng/ul (1.07-156 ng/ul). Of the total 48 FFPE samples, 40 purified by GeneRead and 29 purified by QIAsymphony DSP have DNA concentrations above the functional quantitative range of DIN. The median DIN value was 3.3 and 4.1 for GeneRead and QIAsymphony DSP, respectively.
Conclusions
This study demonstrates that the FFPE pretreatment step has an effect on automated DNA extraction. Highly efficient extraction of FFPE DNA based solely on quantity can be misleading as the DNA may be highly fragmented. The removal of cytosine deamination artifacts from FFPE samples can enhance DNA purification with less degradation. This may also have a crucial influence on the downstream molecular approaches such as DNA sequencing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract